{"disease":{"id":"advanced-melanoma","name":"advanced melanoma"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"relatlimab-rmbw","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OPDUALAG","generic_name":"RELATLIMAB-RMBW","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"opdualag","indication_name":"Advanced melanoma with tumour cell PD-L1 expression below 1%","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Opdualag","company_name":"Australian & New Zealand Children's Haematology/Oncology Group","drug_phase":"marketed","molecular_target":"Lymphocyte activation gene 3 protein","drug_class":"","quality_score":25,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."}],"offLabel":[],"totalMarketed":3,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01511913","title":"A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma","phase":"","overall_status":"COMPLETED","enrollment_count":1411,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05426239","title":"Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database","phase":"","overall_status":"COMPLETED","enrollment_count":1008,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT06028724","title":"A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","phase":"","overall_status":"RECRUITING","enrollment_count":782,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT06112314","title":"IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":680,"lead_sponsor_name":"Immunocore Ltd","has_results":false},{"nct_id":"NCT07079644","title":"Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database","phase":"","overall_status":"COMPLETED","enrollment_count":678,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02658890","title":"An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":627,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06075524","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05581004","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT03273153","title":"A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":446,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06264180","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Replimune, Inc.","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT07371663","title":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"Beijing Tide Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT03941756","title":"Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06899789","title":"Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT01134614","title":"Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":245,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT03114319","title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02857270","title":"A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT07099430","title":"A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT01693068","title":"Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"EMD Serono","has_results":true},{"nct_id":"NCT07280832","title":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT02729298","title":"First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":false},{"nct_id":"NCT04752826","title":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT05094804","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT01621490","title":"PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06090266","title":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT04157985","title":"Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Dan Zandberg","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05267626","title":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":159,"lead_sponsor_name":"Aulos Bioscience, Inc.","has_results":false},{"nct_id":"NCT04462406","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT03917069","title":"Nab-PCE vs PC for MM After Failure of Anti-PD-1","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":145,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT01783938","title":"Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":138,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03815058","title":"A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT06362369","title":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"7 Hills Pharma, LLC","has_results":false},{"nct_id":"NCT03679767","title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03665285","title":"A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"NextCure, Inc.","has_results":true},{"nct_id":"NCT03776136","title":"Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04639219","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03881488","title":"Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Compass Therapeutics","has_results":false},{"nct_id":"NCT07155317","title":"Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":99,"lead_sponsor_name":"Emory University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}